An Overview of Diabetes Management in Schizophrenia Patients: Office Based Strategies for Primary Care Practitioners and Endocrinologists

Diabetes is common and seen in one in five patients with schizophrenia. It is more prevalent than in the general population and contributes to the increased morbidity and shortened lifespan seen in this population. However, screening and treatment for diabetes and other metabolic conditions remain p...

Full description

Saved in:
Bibliographic Details
Main Authors: Aniyizhai Annamalai, Cenk Tek
Format: Article
Language:English
Published: Wiley 2015-01-01
Series:International Journal of Endocrinology
Online Access:http://dx.doi.org/10.1155/2015/969182
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832560902032850944
author Aniyizhai Annamalai
Cenk Tek
author_facet Aniyizhai Annamalai
Cenk Tek
author_sort Aniyizhai Annamalai
collection DOAJ
description Diabetes is common and seen in one in five patients with schizophrenia. It is more prevalent than in the general population and contributes to the increased morbidity and shortened lifespan seen in this population. However, screening and treatment for diabetes and other metabolic conditions remain poor for these patients. Multiple factors including genetic risk, neurobiologic mechanisms, psychotropic medications, and environmental factors contribute to the increased prevalence of diabetes. Primary care physicians should be aware of adverse effects of psychotropic medications that can cause or exacerbate diabetes and its complications. Management of diabetes requires physicians to tailor treatment recommendations to address special needs of this population. In addition to behavioral interventions, medications such as metformin have shown promise in attenuating weight loss and preventing hyperglycemia in those patients being treated with antipsychotic medications. Targeted diabetes prevention and treatment is critical in patients with schizophrenia and evidence-based interventions should be considered early in the course of treatment. This paper reviews the prevalence, etiology, and treatment of diabetes in schizophrenia and outlines office based interventions for physicians treating this vulnerable population.
format Article
id doaj-art-ccf0cf80673c42a9946af2153f3ad1ef
institution Kabale University
issn 1687-8337
1687-8345
language English
publishDate 2015-01-01
publisher Wiley
record_format Article
series International Journal of Endocrinology
spelling doaj-art-ccf0cf80673c42a9946af2153f3ad1ef2025-02-03T01:26:33ZengWileyInternational Journal of Endocrinology1687-83371687-83452015-01-01201510.1155/2015/969182969182An Overview of Diabetes Management in Schizophrenia Patients: Office Based Strategies for Primary Care Practitioners and EndocrinologistsAniyizhai Annamalai0Cenk Tek1Departments of Psychiatry and Internal Medicine, Yale School of Medicine, 34 Park Street, New Haven, CT 06519, USADepartment of Psychiatry, Yale School of Medicine, 34 Park Street, New Haven, CT 06519, USADiabetes is common and seen in one in five patients with schizophrenia. It is more prevalent than in the general population and contributes to the increased morbidity and shortened lifespan seen in this population. However, screening and treatment for diabetes and other metabolic conditions remain poor for these patients. Multiple factors including genetic risk, neurobiologic mechanisms, psychotropic medications, and environmental factors contribute to the increased prevalence of diabetes. Primary care physicians should be aware of adverse effects of psychotropic medications that can cause or exacerbate diabetes and its complications. Management of diabetes requires physicians to tailor treatment recommendations to address special needs of this population. In addition to behavioral interventions, medications such as metformin have shown promise in attenuating weight loss and preventing hyperglycemia in those patients being treated with antipsychotic medications. Targeted diabetes prevention and treatment is critical in patients with schizophrenia and evidence-based interventions should be considered early in the course of treatment. This paper reviews the prevalence, etiology, and treatment of diabetes in schizophrenia and outlines office based interventions for physicians treating this vulnerable population.http://dx.doi.org/10.1155/2015/969182
spellingShingle Aniyizhai Annamalai
Cenk Tek
An Overview of Diabetes Management in Schizophrenia Patients: Office Based Strategies for Primary Care Practitioners and Endocrinologists
International Journal of Endocrinology
title An Overview of Diabetes Management in Schizophrenia Patients: Office Based Strategies for Primary Care Practitioners and Endocrinologists
title_full An Overview of Diabetes Management in Schizophrenia Patients: Office Based Strategies for Primary Care Practitioners and Endocrinologists
title_fullStr An Overview of Diabetes Management in Schizophrenia Patients: Office Based Strategies for Primary Care Practitioners and Endocrinologists
title_full_unstemmed An Overview of Diabetes Management in Schizophrenia Patients: Office Based Strategies for Primary Care Practitioners and Endocrinologists
title_short An Overview of Diabetes Management in Schizophrenia Patients: Office Based Strategies for Primary Care Practitioners and Endocrinologists
title_sort overview of diabetes management in schizophrenia patients office based strategies for primary care practitioners and endocrinologists
url http://dx.doi.org/10.1155/2015/969182
work_keys_str_mv AT aniyizhaiannamalai anoverviewofdiabetesmanagementinschizophreniapatientsofficebasedstrategiesforprimarycarepractitionersandendocrinologists
AT cenktek anoverviewofdiabetesmanagementinschizophreniapatientsofficebasedstrategiesforprimarycarepractitionersandendocrinologists
AT aniyizhaiannamalai overviewofdiabetesmanagementinschizophreniapatientsofficebasedstrategiesforprimarycarepractitionersandendocrinologists
AT cenktek overviewofdiabetesmanagementinschizophreniapatientsofficebasedstrategiesforprimarycarepractitionersandendocrinologists